12 Best Long-Term Stocks to Buy According to Ken Fisher

Page 4 of 12

9. Eli Lilly and Company (NYSE:LLY)

Number of Hedge Fund Holders: 115  

Fisher Asset Management’s Stake: $4 billion 

Eli Lilly and Company (NYSE:LLY) develops and markets human pharmaceuticals. Revenue in the fourth quarter of 2024 increased 45% to $13.53 billion, driven by volume growth from Mounjaro and Zepbound, and non-incretin revenue grew by 20% compared to the fourth quarter of the previous year. In February, the company announced results from the VIVID-2 study, showing that most patients with moderately to severely active Crohn’s disease achieved long-term clinical and endoscopic improvements after two years of continuous treatment with Omvoh. It includes 43.8% of patients who had previously failed biological treatments. In February, Jomfruland reported that the company is revolutionizing diabetes care with an AI-driven metabolic analysis platform that personalizes glucose management, improving medication effectiveness and patient outcomes.

Page 4 of 12